The ShcA PTB domain functions as a biological sensor of phosphotyrosine signaling during breast cancer progression

Cancer Research

Volumn 73, Issue 14, 2013, Pages 4521-4532

  Ahn, Ryuhjin ^a   Sabourin, Valerie ^a   Ha, Jacqueline R ^a   Cory, Sean ^b,c   Maric, Gordana ^c   Im, Young Kyuen ^a   Hardy, W Rod ^d   Zhao, Hong ^c   Park, Morag ^c   Hallett, Michael ^b,c   Siegel, Peter M ^c   Pawson, Tony ^d   Ursini Siegel, Josie ^a  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; FIBROBLAST GROWTH FACTOR RECEPTOR; FIBRONECTIN; PHOSPHOTYROSINE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN SHCA; PROTEIN TYROSINE KINASE; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG; VASCULOTROPIN; VERY LATE ACTIVATION ANTIGEN 5;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; MOUSE; MUTANT; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; DISEASE PROGRESSION; FEMALE; FIBRONECTINS; HUMANS; INTEGRIN ALPHA5BETA1; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, TRANSGENIC; MUTATION; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHOTYROSINE; PROTEIN STRUCTURE, TERTIARY; RECEPTOR PROTEIN-TYROSINE KINASES; SHC SIGNALING ADAPTOR PROTEINS; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84880871624     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-4178     Document Type: Article

References (49)

1. Pelicci G, Lanfrancone L, Grignani F, McGlade J, Cavallo F, Forni G, et al. A novel transforming protein (SHC) with an SH2 domain is implicated in mitogenic signal transduction. Cell 1992;70:93-104.
2. Northey JJ, Chmielecki J, Ngan E, Russo C, Annis MG, Muller WJ, et al. Signaling through ShcA is required for transforming growth factor beta- and Neu/ErbB-2-induced breast cancer cell motility and invasion. Mol Cell Biol 2008;28:3162-76.
3. Ursini-Siegel J, Cory S, Zuo D, Hardy WR, Rexhepaj E, Lam S, et al. Receptor tyrosine kinase signaling favors a protumorigenic state in breast cancer cells by inhibiting the adaptive immune response. Cancer Res 2010;70:7776-87.
4. Ursini-Siegel J, Hardy WR, Zuo D, Lam SH, Sanguin-Gendreau V, Cardiff RD, et al. ShcA signalling is essential for tumour progression in mouse models of human breast cancer. EMBO J 2008;27: 910-20.
5. Lai KM, Pawson T. The ShcA phosphotyrosine docking protein sensitizes cardiovascular signaling in the mouse embryo. Genes Dev 2000;14:1132-45.
6. Smith MJ, Hardy WR, Murphy JM, Jones N, Pawson T. Screening for PTB domain binding partners and ligand specificity using proteomederived NPXY peptide arrays. Mol Cell Biol 2006;26:8461-74.
7. Campbell KS, Ogris E, Burke B, Su W, Auger KR, Druker BJ, et al. Polyoma middle tumor antigen interacts withSHCprotein via theNPTY (Asn-Pro-Thr-Tyr) motif in middle tumor antigen. Proc Natl Acad Sci U S A 1994;91:6344-8.
8. Trub T, Choi WE, Wolf G, Ottinger E, Chen Y, Weiss M, et al. Specificity of the PTB domain of Shc for beta turn-forming pentapeptide motifs amino-terminal to phosphotyrosine. J Biol Chem 1995;270:18205-8.
9. Rozakis-Adcock M, McGlade J, Mbamalu G, Pelicci G, Daly R, Li W, et al. Association of the Shc and Grb2/Sem5 SH2-containing proteins is implicated in activation of the Ras pathway by tyrosine kinases. Nature 1992;360:689-92.
10. van der Geer P, Wiley S, Gish GD, Pawson T. The Shc adaptor protein is highly phosphorylated at conserved, twin tyrosine residues (Y239/240) that mediate protein-protein interactions. Curr Biol 1996;6:1435-44.
11. Ursini-Siegel J, Hardy WR, Zheng Y, Ling C, Zuo D, Zhang C, et al. The ShcA SH2 domain engages a 14-3-3/PI30K signaling complex and promotes breast cancer cell survival. Oncogene 2012;31:5038-44.
12. Guy CT, Cardiff RD, Muller WJ. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol 1992;12:954-61.
13. Hardy WR, Li L, Wang Z, Sedy J, Fawcett J, Frank E, et al. Combinatorial ShcA docking interactions support diversity in tissue morphogenesis. Science 2007;317:251-6.
14. Han F, Adams CS, Tao Z, Williams CJ, Zaka R, Tuan RS, et al. Transforming growth factor-beta1 (TGF-beta1) regulates ATDC5 chondrogenic differentiation and fibronectin isoform expression. J Cell Biochem 2005;95:750-62.
15. Bell D, Berchuck A, Birrer M, Chien J, Cramer D, Dao F, et al. Integrated genomic analyses of ovarian carcinoma. Nature 2011;474:609-15.
16. Chen DT, Nasir A, Culhane A, Venkataramu C, Fulp W, Rubio R, et al. Proliferative genes dominate malignancy-risk gene signature in histologically- normal breast tissue. Breast Cancer Res Treat 2010;119: 335-46.
17. Hatzis C, Pusztai L, Valero V, Booser DJ, Esserman L, Lluch A, et al. A genomic predictor of response and survival following taxane- anthracycline chemotherapy for invasive breast cancer. JAMA 2011;305:1873-81.
18. Loi S, Haibe-Kains B, Desmedt C, Wirapati P, Lallemand F, Tutt AM, et al. Predicting prognosis using molecular profiling in estrogen receptor- positive breast cancer treated with tamoxifen. BMC Genomics 2008;9:239.
19. van de Vijver MJ, HeYD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, et al. Agene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999-2009.
20. van Vliet MH, Reyal F, Horlings HM, van de Vijver MJ, Reinders MJ, Wessels LF. Pooling breast cancer datasets has a synergetic effect on classification performance and improves signature stability. BMC Genomics 2008;9:375.
21. Webster MA, Hutchinson JN, Rauh MJ, Muthuswamy SK, Anton M, Tortorice CG, et al. Requirement for both Shc and phosphatidylinositol 30 kinase signaling pathways in polyomavirus middle T-mediated mammary tumorigenesis. Mol Cell Biol 1998;18:2344-59.
22. Lin EY, Li JF, Gnatovskiy L, Deng Y, Zhu L, Grzesik DA, et al. Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res 2006;66:11238-46.
23. Dankort D, Jeyabalan N, Jones N, Dumont DJ, Muller WJ. Multiple ErbB-2/Neu phosphorylation sites mediate transformation through distinct effector proteins. J Biol Chem 2001;276:38921-8.
24. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82.
25. Sakurai T, Kudo M. Signaling pathways governing tumor angiogenesis. Oncology 2011;81 Suppl 1:24-9.
26. You WK, McDonald DM. The hepatocyte growth factor/c-Met signaling pathway as a therapeutic target to inhibit angiogenesis. BMB Rep 2008;41:833-9.
27. Guo W, Giancotti FG. Integrin signalling during tumour progression. Nat Rev Mol Cell Biol 2004;5:816-26.
28. Huck L, Pontier SM, Zuo DM, Muller WJ. Beta1-integrin is dispensable for the induction of ErbB2 mammary tumors but plays a critical role in the metastatic phase of tumor progression. Proc Natl Acad Sci U S A 2010;107:15559-64.
29. Coltrini D, Ronca R, Belleri M, Zardi L, Indraccolo S, Scarlato V, et al. Impact of VEGF-dependent tumour micro-environment on EDB fibronectin expression by subcutaneous human tumour xenografts in nude mice. J Pathol 2009;219:455-62.
30. Lo KM, Lan Y, Lauder S, Zhang J, Brunkhorst B, Qin G, et al. huBC1- IL12, an immunocytokine which targets EDB-containing oncofetal fibronectin in tumors and tumor vasculature, shows potent anti-tumor activity in human tumor models. Cancer Immunol Immunother 2007; 56:447-57.
31. Villa A, Trachsel E, Kaspar M, Schliemann C, Sommavilla R, Rybak JN, et al. A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo. Int J Cancer 2008;122:2405-13.
32. Ravichandran KS, Zhou MM, Pratt JC, Harlan JE, Walk SF, Fesik SW, et al. Evidence for a requirement for both phospholipid and phosphotyrosine binding via the Shc phosphotyrosine-binding domain in vivo. Mol Cell Biol 1997;17:5540-9.
33. Schuller AC, Ahmed Z, Levitt JA, Suen KM, Suhling K, Ladbury JE. Indirect recruitment of the signalling adaptor Shc to the fibroblast growth factor receptor 2 (FGFR2). Biochem J 2008;416:189-99.
34. Smith MJ, Hardy WR, Li GY, Goudreault M, Hersch S, Metalnikov P, et al. The PTB domain of ShcA couples receptor activation to the cytoskeletal regulator IQGAP1. EMBO J 2010;29:884-96.
35. Kraut-Cohen J, Muller WJ, Elson A. Protein-tyrosine phosphatase epsilon regulates Shc signaling in a kinase-specific manner: increasing coherence in tyrosine phosphatase signaling. J Biol Chem 2008;283: 4612-21.
36. Zou L, Cao S, Kang N, Huebert RC, Shah VH. Fibronectin induces endothelial cell migration through beta1 integrin and Src-dependent phosphorylation of fibroblast growth factor receptor-1 at tyrosines 653/654 and 766. J Biol Chem 2012;287:7190-202.
37. Mitra AK, Sawada K, Tiwari P, Mui K, Gwin K, Lengyel E. Ligandindependent activation of c-Met by fibronectin and alpha(5)beta(1)- integrin regulates ovarian cancer invasion and metastasis. Oncogene 2011;30:1566-76.
38. Hollenbeck ST, Itoh H, Louie O, Faries PL, Liu B, Kent KC. Type I collagen synergistically enhances PDGF-induced smooth muscle cell proliferation through pp60src-dependent crosstalk between the alpha2beta1 integrin and PDGFbeta receptor. Biochem Biophys Res Commun 2004;325:328-37.
39. Dans M, Gagnoux-Palacios L, Blaikie P, Klein S, Mariotti A, Giancotti FG. Tyrosine phosphorylation of the beta 4 integrin cytoplasmic domain mediates Shc signaling to extracellular signal-regulated kinase and antagonizes formation of hemidesmosomes. J Biol Chem 2001; 276:1494-502.
40. Deshmukh L, Gorbatyuk V, Vinogradova O. Integrin {beta}3 phosphorylation dictates its complex with the Shc phosphotyrosine-binding (PTB) domain. J Biol Chem 2010;285:34875-84.
41. Wary KK, Mariotti A, Zurzolo C, Giancotti FG. A requirement for caveolin-1 and associated kinase Fyn in integrin signaling and anchorage- dependent cell growth. Cell 1998;94:625-34.
42. Sato K, Nagao T, Kakumoto M, Kimoto M, Otsuki T, Iwasaki T, et al. Adaptor protein Shc is an isoform-specific direct activator of the tyrosine kinase c-Src. J Biol Chem 2002;277:29568-76.
43. Sato K, Gotoh N, Otsuki T, Kakumoto M, Aoto M, Tokmakov AA, et al. Tyrosine residues 239 and 240 of Shc are phosphatidylinositol 4, 5- bisphosphate-dependent phosphorylation sites by c-Src. Biochem Biophys Res Commun 1997;240:399-404.
44. Lahlou H, Sanguin-Gendreau V, Zuo D, Cardiff RD, McLeanGW, Frame MC, et al.Mammary epithelial-specific disruption of the focal adhesion kinase blocks mammary tumor progression. Proc Natl Acad Sci U S A 2007;104:20302-7.
45. Marcotte R, Smith HW, Sanguin-Gendreau V, McDonough RV, Muller WJ. Mammary epithelial-specific disruption of c-Src impairs cell cycle progression and tumorigenesis. Proc Natl Acad Sci U S A 2012;109: 2808-13.
46. Ponzo MG, Lesurf R, Petkiewicz S, O'Malley FP, Pinnaduwage D, Andrulis IL, et al. Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer. Proc Natl Acad Sci U S A 2009;106:12903-8.
47. Lieskovska J, Ling Y, Badley-Clarke J, Clemmons DR. The role of Src kinase in insulin-like growth factor-dependent mitogenic signaling in vascular smooth muscle cells. J Biol Chem 2006;281:25041-53.
48. Nguyen L, Holgado-Madruga M, Maroun C, Fixman ED, Kamikura D, Fournier T, et al. Association of the multisubstrate docking protein Gab1 with the hepatocyte growth factor receptor requires a functional Grb2 binding site involving tyrosine 1356. J Biol Chem 1997;272: 20811-9.
49. Schlaepfer DD, Jones KC, Hunter T. Multiple Grb2-mediated integrin- stimulated signaling pathways to ERK2/mitogen-activated protein kinase: summation of both c-Src- and focal adhesion kinaseinitiated tyrosine phosphorylation events. Mol Cell Biol 1998;18: 2571-85.